Key result
Low-molecular-weight heparins are the preferred agents for preventing and treating venous thromboembolism during pregnancy, with dosage tailored to the specific risk profile and thrombophilia.
Low-molecular-weight heparin is the preferred pharmacological agent for the prevention and treatment of venous thromboembolism during pregnancy, while oral anticoagulants can be safely used postpartum.
Authors
No takes yet. Share an insight, caveat, or question.
Supports LMWH preference for pregnancy VTE; leaves open prospective validation of risk-tailored dosing by thrombophilia.
Attila Pajor (2011) conducted a review in Venous thromboembolism in pregnancy. Low-molecular-weight heparin (LMWH) was evaluated. Low-molecular-weight heparins are the preferred agents for preventing and treating venous thromboembolism during pregnancy, with dosage tailored to the specific risk profile and thrombophilia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: